Follow
David Church
Title
Cited by
Cited by
Year
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
OJ Skrede, S De Raedt, A Kleppe, TS Hveem, K Liestřl, J Maddison, ...
The Lancet 395 (10221), 350-360, 2020
4202020
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ...
Modern pathology 28 (6), 836-844, 2015
4202015
DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer
DN Church, SEW Briggs, C Palles, E Domingo, SJ Kearsey, JM Grimes, ...
Human molecular genetics 22 (14), 2820-2828, 2013
3882013
A panoply of errors: polymerase proofreading domain mutations in cancer
E Rayner, IC Van Gool, C Palles, SE Kearsey, T Bosse, I Tomlinson, ...
Nature Reviews Cancer 16 (2), 71-81, 2016
3382016
Insulin‐like growth factor ligands, receptors, and binding proteins in cancer
E Foulstone, S Prince, O Zaccheo, JL Burns, J Harper, C Jacobs, ...
The Journal of Pathology: A Journal of the Pathological Society of Great …, 2005
3072005
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
DN Church, E Stelloo, RA Nout, N Valtcheva, J Depreeuw, N Ter Haar, ...
Journal of the National Cancer Institute 107 (1), dju402, 2015
3042015
POLE proofreading mutations elicit an antitumor immune response in endometrial cancer
IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ...
Clinical Cancer Research 21 (14), 3347-3355, 2015
2992015
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ...
The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016
2782016
Practical guidance for mismatch repair-deficiency testing in endometrial cancer
E Stelloo, AML Jansen, EM Osse, RA Nout, CL Creutzberg, D Ruano, ...
Annals of Oncology 28 (1), 96-102, 2017
2722017
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis
D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ...
Journal of Clinical Oncology 32 (10), 1031, 2014
2582014
Clinicopathological and molecular characterisation of ‘multiple‐classifier’endometrial carcinomas
A León‐Castillo, E Gilvazquez, R Nout, VT Smit, JN McAlpine, ...
The Journal of pathology 250 (3), 312-322, 2020
2412020
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer
E Domingo, DN Church, O Sieber, R Ramamoorthy, Y Yanagisawa, ...
J clin Oncol 31 (34), 4297-4305, 2013
2382013
Interpretation of somatic POLE mutations in endometrial carcinoma
A León‐Castillo, H Britton, MK McConechy, JN McAlpine, R Nout, ...
The Journal of pathology 250 (3), 323-335, 2020
2332020
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome
EJ Crosbie, NAJ Ryan, MJ Arends, T Bosse, J Burn, JM Cornes, ...
Genetics in Medicine 21 (10), 2390-2400, 2019
1922019
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
RS Kerr, S Love, E Segelov, E Johnstone, B Falcon, P Hewett, A Weaver, ...
The Lancet Oncology 17 (11), 1543-1557, 2016
1652016
CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer
FL Komdeur, TM Prins, S van de Wall, A Plat, GBA Wisman, H Hollema, ...
Oncoimmunology 6 (9), e1338230, 2017
1642017
Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi, M Artibani, JD Brenton, SM Curbishley, ...
British journal of cancer 124 (11), 1759-1776, 2021
1592021
A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
HH Workel, JM Lubbers, R Arnold, TM Prins, P van der Vlies, K de Lange, ...
Cancer immunology research 7 (5), 784-796, 2019
1532019
Frequent homologous recombination deficiency in high-grade endometrial carcinomas
MM de Jonge, A Auguste, LM van Wijk, PC Schouten, M Meijers, ...
Clinical Cancer Research 25 (3), 1087-1097, 2019
1382019
Survivin in solid tumors: rationale for development of inhibitors
DN Church, DC Talbot
Current oncology reports 14, 120-128, 2012
1372012
The system can't perform the operation now. Try again later.
Articles 1–20